139 related articles for article (PubMed ID: 35447282)
21. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
22. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
24. The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance.
Liu Y; Gu JJ; Yang L; Tsai PC; Guo Y; Xue K; Xia Z; Liu X; Lv F; Cao J; Hong X; Mavis C; Hernandez-Ilizaliturri FJ; Zhang Q
Aging (Albany NY); 2020 Dec; 13(1):181-193. PubMed ID: 33288735
[TBL] [Abstract][Full Text] [Related]
25. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
27. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.
Mahadevan D; Morales C; Cooke LS; Manziello A; Mount DW; Persky DO; Fisher RI; Miller TP; Qi W
PLoS One; 2014; 9(6):e95184. PubMed ID: 24893165
[TBL] [Abstract][Full Text] [Related]
28. Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.
Thomsen EA; Rovsing AB; Anderson MV; Due H; Huang J; Luo Y; Dybkaer K; Mikkelsen JG
Mol Oncol; 2020 Sep; 14(9):1978-1997. PubMed ID: 32585766
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
30. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
31. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
32. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
[TBL] [Abstract][Full Text] [Related]
33. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
34. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K
Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
37. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
38. The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
Park LC; Song YJ; Kim DJ; Kim MJ; Jo JC; Lee WS; Shin HJ; Oh SY; Do YR; Jeong JY; Lee HS;
Int J Cancer; 2019 Nov; 145(9):2459-2467. PubMed ID: 30973963
[TBL] [Abstract][Full Text] [Related]
39. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
Sert F; Kamer S; Saydam G; Anacak Y
J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
[TBL] [Abstract][Full Text] [Related]
40. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]